Advertisement

Breast Cancer Research and Treatment

, Volume 160, Issue 1, pp 41–49 | Cite as

Use of a multiplexed immunoassay (PRO Onc assay) to detect HER2 abnormalities in circulating tumor cells of women with HER2-negative metastatic breast cancer: lack of response to HER2-targeted therapy

  • John D. Hainsworth
  • Patrick B. Murphy
  • Jose R. Alemar
  • Brooke R. Daniel
  • Robyn R. Young
  • Denise A. Yardley
Clinical Trial

Abstract

Purpose

Determination of HER2 status by testing circulating tumor cells (CTCs), compared to sampling tumor biopsies, may improve patient management by allowing ongoing assessment of HER2 status during the disease course. The PRO Onc assay (Prometheus Laboratories; San Diego, CA) is a multiplexed immunoassay that measures the expression and activation of HER2 in CTCs. In this study, we screened patients with metastatic HER2-negative breast cancer with the PRO Onc assay; patients with HER2 overexpression or activation received a trial of HER2-targeted therapy.

Methods

In Part 1 of the trial, patients with HER2-negative breast cancer were screened with the PRO Onc assay to confirm the presence of a cohort that tested HER2-positive. After this finding was confirmed, patients in Part 2 of the study with HER2 abnormalities received a trial of treatment with trastuzumab/pertuzumab.

Results

In Part 1, 31 of 57 specimens contained CTCs; of these, 12 (38 %) showed HER2 abnormalities by PRO Onc assay. In Part 2, 129 of 226 patients (57 %) had CTCs; 24 of these patients (19 %) had HER2 abnormalities detected. Fourteen patients were treated with HER2-targeted therapy. Twelve of 14 patients progressed within 6 weeks, one patient had a brief (12 weeks) partial response, and one patient was stable for 12 weeks.

Conclusions

HER2 overexpression or activation was detected by the PRO Onc assay in 22 % of HER2-negative patients with CTCs. However, HER2-targeted therapy was not effective in such patients. FISH and IHC staining remain the standards for HER2 determination.

Keywords

HER2-negative HER2 abnormalities PRO Onc assay 

Notes

Acknowledgments

This study was supported in part by Grants from Prometheus Labs and Genentech-Roche.

Compliance with ethical standards

Conflict of interest

JDH received funding to his institution for the study from Genentech and Prometheus. All the other authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Pegram MD, Pienkowski T, Northfelt DW et al (2004) Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer. J Natl Cancer Inst 96:759–769CrossRefPubMedGoogle Scholar
  2. 2.
    Robert N, Leyland-Jones B, Asmar L et al (2006) Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol 24:2786–2792CrossRefPubMedGoogle Scholar
  3. 3.
    Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659–1672CrossRefPubMedGoogle Scholar
  4. 4.
    Slamon D, Eiermann W, Robert N et al (2011) Adjuvant trastuzumab in HER2-positive breast cancer. N Eng J Med 365:1273–1283CrossRefGoogle Scholar
  5. 5.
    Lebeau A, Deimling D, Kaltz C et al (2001) HER-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization. J Clin Oncol 19:354–363PubMedGoogle Scholar
  6. 6.
    Gomez HL, Doval DC, Chavez MA et al (2008) Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer. J Clin Oncol 26:2999–3005CrossRefPubMedGoogle Scholar
  7. 7.
    Agus DB, Gordon MS, Taylor C et al (2005) Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Oncol 23:2534–2543CrossRefPubMedGoogle Scholar
  8. 8.
    Lindstrom LS, Karlsson E, Wilking UM et al (2012) Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. J Clin Oncol 30:2601–2608CrossRefPubMedGoogle Scholar
  9. 9.
    Fehm T, Muller V, Aktas B et al (2010) HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective multicenter trial. Breast Cancer Res Treat 102:1495–1502Google Scholar
  10. 10.
    Pestrin M, Bessi S, Galardi F et al (2009) Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients. Breast Cancer Res Treat 118:523–530CrossRefPubMedGoogle Scholar
  11. 11.
    Liu L, Kim P, Liu X et al (2009) Novel method to detect activation of ErbB family receptor tyrosine kinases. AACR, Denver (#5260) Google Scholar
  12. 12.
    Kim P, Liu X, Lee T et al (2011) Highly sensitive proximity mediated immunoassay reveals HER2 status conversion in the circulating tumor cells of metastatic breast cancer patients. Proteom Sci 9:75CrossRefGoogle Scholar
  13. 13.
    Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247CrossRefPubMedGoogle Scholar
  14. 14.
    Cobleigh MA, Vogel CA, Tripathy D et al (1999) Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17:2639–2648PubMedGoogle Scholar
  15. 15.
    Gerlinger M, Rowan AJ, Horswell S et al (2012) Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366:883–892CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Simoncini T, Hafezi-Moghadam A, Brazil DP et al (2000) Interaction of the oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature 407:538–541CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    de Graffenried LA, Friedrichs WE, Russell DH et al (2004) Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt activity. Clin Cancer Res 10:8059–8067CrossRefGoogle Scholar
  18. 18.
    Rothe F, Laes JF, Lambrechts D et al (2014) Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer. Ann Oncol 25:1959–1965CrossRefPubMedGoogle Scholar
  19. 19.
    Forte VA, Barrak DK, Elhodaky M et al (2016) The potential for liquid biopsies in the precision medical treatment of breast cancer. Cancer Biol Med 13:19–40CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Meng S, Tripathy D, Shete S et al (2004) HER2 gene amplification can be acquired as breast cancer progresses. PNAS 101:9393–9398CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Riethdorf S, Fritsche H, Muller V et al (2007) Detection of circulating tumor cells in the peripheral blood of patients with metastatic breast cancer: a validation study of the cell search system. Clin Cancer Res 13:920–928CrossRefPubMedGoogle Scholar
  22. 22.
    Pierga JY, Hajage D, Bachelot T et al (2012) High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients. Ann Oncol 23:618–624CrossRefPubMedGoogle Scholar
  23. 23.
    Baselga J, Gelmon KA, Verma S et al (2010) Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol 28:1138–1144CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Wakelee HA et al (2016) Epidermal growth factor receptor (EGFR) genotyping of matched urine, plasma and tumor tissue from non-small cell lung cancer (NSCLC) patients treated with rociletinib. J Clin Oncol 34(Suppl):456s (Abstract #9001) Google Scholar
  25. 25.
    Kurbacher CM et al (2016) Anti-HER2 treatment in advanced metastatic HER2-negative breast cancer patients with elevated serum levels of the HER2 extracellular domain and/or HER2 overexpressing circulating tumor cells. J Clin Oncol 34(Suppl):33s (Abstract #597) Google Scholar
  26. 26.
    Albrecht S, Schochter F, Melcher CA et al (2014) DETECT III/IV: two combined clinical trials based on the phenotype of circulating tumor cells (CTCs). J Clin Oncol 32(Suppl):727s (Abstract TPS11132) Google Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  • John D. Hainsworth
    • 1
    • 2
  • Patrick B. Murphy
    • 2
  • Jose R. Alemar
    • 3
  • Brooke R. Daniel
    • 4
  • Robyn R. Young
    • 5
  • Denise A. Yardley
    • 1
    • 2
  1. 1.Sarah Cannon Research InstituteNashvilleUSA
  2. 2.Tennessee Oncology, PLLCNashvilleUSA
  3. 3.Florida Cancer SpecialistsClearwaterUSA
  4. 4.Tennessee Oncology, PLLCChattanoogaUSA
  5. 5.The Center for Cancer and Blood DisordersFort WorthUSA

Personalised recommendations